Floatz Rating
D30/100
Confidence
Indicative
Sponsor
Ankara City Hospital Bilkent
Modality
Small molecule
Development Phase
N/A
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
15Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07607691CT.gov Ultrasound-Guided PENG Block for Chronic Shoulder Pain | — | Not Yet Recruiting | — | — | — |
NCT05980572CT.gov Effects of App-assisted Home Exercise Program in Patients With Frozen Shoulder | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Frozen Shoulder
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Lidocaine (this asset) | Ankara City Hospital Bilkent | N/A | D · 30 |
| Dexasone | Ankara City Hospital Bilkent | N/A | D |
| Kenacort | Chang Gung Memorial Hospital | N/A | D |
| Dextrose | Rizki Darmawan | N/A | D |
| Aceclofenac | Chang Gung Memorial Hospital | N/A | D |
| Marcaine | Federal University of São Paulo | N/A | D |
| Ibuprofen | Konya Beyhekim Training and Research Hospital | N/A | D |
| Aspirin | Assiut University | N/A | D |
Other indications for Lidocaine
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Peripheral Neuropathy | — | P4 | BBB · 79 |
| Postherpetic Neuralgia | — | P4 | BBB · 78 |
| Post-Operative Pain, Non-Human Animal | — | P4 | BBB · 76 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Lidocaine in Frozen Shoulder. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/lidocaine-frozen-shoulder
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →